HTA and Reimbursement Status of Metastatic Hormone‑Sensitive Prostate Cancer, Non-Metastatic Castration-Resistant Prostate Cancer, and Metastatic Castration-Resistant Prostate Canc... by Goran Bencina, Elina Petrova, Demet Sönmez, Sonia Matos Pereira, Ioannis Dimitriadis, Stina Salomonsson

“…To improve decision-making regarding the value of anticancer therapies and support standardized assessment for use by health technology assessment (HTA) agencies, the European Society for Medical Oncology (ESMO) has developed a Magnitude of Clinical Benefit Scale (MCBS). …”
Get full text

Awardee Summary of 2023 Taiwan Oncology Society Clinical Research Award Recipient: Persistent Endeavors on Research of Digestive Cancers for Three Decades by Kun-Huei Yeh

“…Third, on behalf of the Taiwan Oncology Society, we participated in and published the Pan-Asian adapted European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for locally advanced and metastatic CRC, gastric, and esophageal cancers, and the consensus meeting on tumor-agnostic indications of microsatellite instability-high (MSI-H) and NTRK. …”
Get full text

Comparative efficacy and safety of neoadjuvant radiotherapy for patients with borderline resectable, and locally advanced pancreatic ductal adenocarcinoma: a systematic review and... by Xin Wang, Dan Cao, Qingfeng Wang, Qiancheng Hu, Wanrui Lv

“…Electronic searching by titles using neoadjuvant treatments for PDAC will be performed in the annual meetings of European Society of Medical Oncology and American Society of Clinical Oncology (2018–2020). …”
Get full text

The impact of integrated genomic analysis on molecular classifications and prognostic risk stratification in endometrial cancer: a Chinese experience by Qian Zheng, Qian Zheng, Qian Zheng, Di Shao, Jin Shu, Jin Shu, Jin Shu, Qin Zhang, Qin Zhang, Qin Zhang, Min Huang, Dong Wang, Dong Wang, Dong Wang, Dongling Zou, Dongling Zou, Dongling Zou

“…With the application of the new European Society for Medical Oncology (ESMO) 2022 classification, 27 patients (14.1%) were reclassified. …”
Get full text

Clinical integration of germline findings from a tumor testing precision medicine program by Maria Carolina Sanabria-Salas, Nina C. Anggala, Brittany Gillies, Kirsten M. Farncombe, Renee Hofstedter, Larissa Peck, Helia Purnaghshband, Laura Redondo, Emily Thain, Wei Xu, Peter Sabatini, Philippe L. Bedard, Raymond H. Kim

“…Germline-focused analysis of TGVs followed the European Society of Medical Oncology guidelines and similar published criteria (‘tumor-only criteria’). …”
Get full text

Clinical Utility of Combined Tissue and Plasma Next-Generation Sequencing in Patients With Advanced, Treatment-Naïve NSCLC by Helena Bote-de Cabo, MD, Marco Siringo, MD, Esther Conde, MD, PhD, Susana Hernández, PhD, Fernando López-Ríos, MD, PhD, Alicia Castelo-Loureiro, MD, Esther García-Lorenzo, MD, Javier Baena, MD-PhD, Mercedes Herrera, MD, Ana Belén Enguita, MD, Yolanda Ruano, PhD, Jon Zugazagoitia, MD, PhD, Luis Paz-Ares, MD, PhD

“…Results: Forty-three patients in cohort 1 (34%) and 49 patients in cohort 2 (33%) harbored European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets (ESCAT) I or II targetable driver alterations. …”
Get full text